The present invention relates to a composition for topical administration comprising a colloidal oatmeal and a 4-t-butylcyclohexanol, wherein the colloidal oatmeal comprises β-glucan and optionally avenanthramide. The 4-t-butylcyclohexanol is in an amount in the range of 0.1-5 wt % of the total amount of the composition, and the β-glucan is in an amount in the range of 1-10 wt % of the total amount of the composition. The present invention further relates to said composition for topical administration for use in therapy and said composition for topical administration for use in treating or preventing a skin condition associated with cancer radiation therapy or chemotherapy, and also the use of said composition in treating or preventing a skin condition associated with cancer radiation therapy or chemotherapy.
A61K 36/886 - Aloeaceae (famille de l'aloès), p. ex. aloe vera
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
2.
COMPOSITIONS AND METHODS FOR THE PREVENTION AND MANAGEMENT OF RADIATION DERMATITIS AND HAND-FOOT SYNDROME
A61K 131/00 - Parties de plantes contenant des graines ou des semences, des noix ou des noisettes, des fruits ou des grains, ou obtenues à partir de ces éléments
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
3.
COMPOSITIONS AND METHODS FOR THE PREVENTION AND MANAGEMENT OF RADIATION DERMATITIS AND HAND-FOOT SYNDROME
The present invention relates to a composition for topical administration comprising a colloidal oatmeal and a 4-t-butylcyclohexanol, wherein the colloidal oatmeal comprises β- glucan and optionally avenanthramide. The 4-t-butylcyclohexanol is in an amount in the range of 0.1-5 wt % of the total amount of the composition, and the β-glucan is in an amount in the range of 1-10 wt % of the total amount of the composition. The present invention further relates to said composition for topical administration for use in therapy and said composition for topical administration for use in treating or preventing a skin condition associated with cancer radiation therapy or chemotherapy, and also the use of said composition in treating or preventing a skin condition associated with cancer radiation therapy or chemotherapy.
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
A61K 131/00 - Parties de plantes contenant des graines ou des semences, des noix ou des noisettes, des fruits ou des grains, ou obtenues à partir de ces éléments